Distinct cutaneous α-synuclein signatures in body-first and brain-first Parkinson’s disease subtypes

Le résumé fourni par la source

Parkinson's disease (PD) is characterized by pathological α-synuclein (α-syn) aggregation, yet the origin of α-syn pathology (central or peripheral) remains debated. The synuclein origin and connectome model proposes two subtypes, i.e. brain-first (pathology initiating in brain structures) and body-first (originating in peripheral autonomic nerves) subtypes. In this study, we aimed to delineate cutaneous α-syn signatures between these subtypes to validate the synuclein origin and connectome model. In this cross-sectional study, 126 brain-first PD patients, 79 body-first PD patients and 60 healthy controls were enrolled. Subtype classification was based on the presence of REM sleep behaviour disorder preceding motor symptoms. All participants underwent skin biopsies at two anatomical sites: the distal leg (DL) and the posterior cervical region (C7). Intraepidermal, sudomotor and pilomotor nerve fibre densities were quantified. Phosphorylated α-syn (p-α-syn) deposition was assessed by immunostaining, and α-syn seeding activity was evaluated using real-time quaking-induced conversion. Clinical correlations and diagnostic performance were analysed systematically. Body-first PD patients exhibited more prominent non-motor symptoms (e.g. REM sleep behaviour disorder, autonomic dysfunction) and severe autonomic denervation (reduced sweat gland and pilomotor nerve densities; P < 0.01). Immunostaining revealed significantly higher p-α-syn positivity (92.4% versus 61.9%) and a greater p-α-syn diffusion coefficient (0.2 versus 0.0) in body-first versus brain-first PD patients. Body-first PD patients displayed a distal-to-proximal α-syn gradient (DL, 86.1% versus C7. 55.7%), contrasting with the proximal-dominant pattern in brain-first PD patients (DL, 40.5% versus C7, 50.8%). Body-first PD patients also demonstrated accelerated α-syn seeding activity (higher maximum fluorescence intensity, shorter time to reach threshold; P < 0.001). Cutaneous α-syn parameters were correlated strongly with non-motor symptom severity in body-first PD patients (P < 0.05). Receiver operating characteristic analysis showed that DL α-syn signatures have discriminative power for subtype differentiation (area under the curve = 0.774). Our findings provide direct pathological evidence for the body-first versus brain-first PD framework and highlight the value of skin biopsy as a minimally invasive biomarker for PD subtyping. This study contributes to precision medicine approaches targeting α-syn pathology-specific propagation pathways in PD.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.